Enzyme immunoassay for the quantitative determination of specific Ipilimumab(Yervoy®) in human serum and plasma.
This kit has been especially developed for the quantitative determination of ipilimumab in serum and plasma samples between the Cmin and Cmax range of concentrations.
Ipilimumab Drug Bank Accession Number is DB06186.
Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. Ipilimumab binds to CTLA-4 on the cell surface, effectively blocking the interaction between CTLA-4 and B7.1/B7.2. This leads to interruption of the negative signal mediated by CTLA-4, the resumption of signal 2, and a relative restoration of T-cell activation. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
| Required Volume (µl) | 10 |
| Total Time (min) | 70 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 3 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
Reviews
There are no reviews yet.